TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26310855
Drug: Topical anesthetic
Normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical anesthetic (EMLA® or Numby®) plus subcutaneous buffered lidocaine (SQBL)
Study: 26310855
Drug: Topical anesthetic
Normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical anesthetic (EMLA® or Numby®) only
Study: 26310855
Drug: Topical anesthetic
Normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical anesthetic (EMLA® or Numby®) plus SQBL
Study: 23526241
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg and Aspirin 150 mg capsule (test formulation)
Study: 23526241
Drug: Lipitor® tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipitor® tablets 10 mg and Nu‐Seals tablets 75 mg (reference formulations)
Study: 17709266
Drug: i.v. AG
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. AG supplementation (0.3 g/kg day from day 4 till 17) and i.v. GH (0.05 mg/kg day divided into 8 boluses, maximum dose at 3 AM, administered on days 7‐17)
Study: 12891293
Drug: Ticlopidine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine (1000 mg/day for 2 days and then 500 mg/day for 5 days, n=19)
Study: 12891293
Drug: Clopidogrel (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300 mg/day for 1 day and then 75 mg/day for 6 days, n=10)
Study: 10440606
Drug: Omeprazole (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (10-20 mg for 4 weeks)
Study: 23657065
Drug: QD of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD of 400 mL/min with QB of 200 mL/min
Study: 23657065
Drug: QD of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD of 400 mL/min with QB of 210 mL/min (condition B')
Study: 23657065
Drug: QD of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD of 500 mL/min with QB of 200 mL/min (condition A)
Study: 23657065
Drug: QD of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD of 500 mL/min with QB of 150 mL/min (condition B)
Study: 20959524
Drug: Single doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of dexpramipexole (50 mg, 150 mg, or 300 mg)
Study: 20959524
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of dexpramipexole (50 mg twice daily, 100 mg twice daily, or 150 mg twice daily) over 4.5 days
Study: 20959524
Drug: Single doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of dexpramipexole
Study: 11406789
Drug: TiO2-blasted implants
Normalized name: Titanium Dioxide
DrugBank: Titanium dioxide (DB09536)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TiO2-blasted implants
Study: 9760898
Drug: Machined implants
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Machined implants
Study: 8988821
Drug: Epidural ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural ketamine + morphine with lidocaine before surgical incision
Study: 8988821
Drug: General anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anaesthesia (group G)
Study: 8988821
Drug: Epidural ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural ketamine + morphine with lidocaine after skin incision (group EA)
Study: 24034302
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of QRS duration and mean energy in the high frequency band
Study: 22542366
Drug: Etonogestrel (ENG)‐releasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etonogestrel (ENG)‐releasing implant inserted 24‐48 h after delivery (implant group; n=20)
Study: 1354392
Drug: Intravenous 50
Normalized name: immune globulin intravenous 50 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 50 mg bolus of chimaeric anti-CD4 monoclonal antibody (cM-T412)
Study: 1354392
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg weekly for four consecutive weeks of chimaeric anti-CD4 monoclonal antibody (cM-T412)
Study: 6147836
Drug: LORMetazepam 2
Normalized name: lormetazepam 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: LORMetazepam 2 mg
Study: 6147836
Drug: FLUNitrazepam 2
Normalized name: flunitrazepam 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLUNitrazepam 2 mg
Study: 6147836
Drug: FLURazepam 30
Normalized name: flurazepam 30 mg oral capsule
DrugBank: Flurazepam (DB00690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FLURazepam 30 mg
Study: 6147836
Drug: DIAZepam 10
Normalized name: diazepam 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: DIAZepam 10 mg
Study: 30949243
Drug: Calf muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calf muscle eccentric exercise program (twice a day, 7 days a week, for 12 weeks)
Study: 28528475
Drug: 200 μg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μg/day selenium supplements
Study: 26865420
Drug: Breathe Right
Normalized name: BREATHE RIGHT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breathe Right Nasal Strip (BRNS) + Decongestant
Study: 25379858
Drug: TAC-STER (tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAC-STER (tacrolimus short-term steroid)
Study: 19858777
Drug: Budesonide 400
Normalized name: Budesonide 400 microgram/actuation powder for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 400 microg twice daily for 1 month, then 200 microg twice daily for 5 months
Study: 19858777
Drug: Budesonide 100
Normalized name: budesonide 100 MCG/ACTUAT Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 100 microg twice daily for 1 year
Study: 18022468
Drug: Tramadol 50
Normalized name: traMADol 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 50 mg intramuscularly (Group T)
Study: 18022468
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium 75 mg intramuscularly (Group D)
Study: 15617966
Drug: Implants placed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implants placed in grafted bone (222 implants)
Study: 15617966
Drug: Brånemark implants
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brånemark implants in non-grafted bone (75 implants)
Study: 15617966
Drug: Implants placed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implants placed in grafted bone
Study: 15617966
Drug: Implants with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implants with low primary stability (20 implants)
Study: 15617966
Drug: Failed implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Failed implants
Study: 7607378
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg oxybutynin administered intravesically
Study: 7607378
Drug: Placebo (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (40 ml sterile sodium chloride solution) administered intravesically
Study: 1977153
Drug: Cetirizine (evening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine (evening administration)
Study: 1977153
Drug: Cetirizine (morning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine (morning administration)
Study: 707970
Drug: L-tryptophan (0.5-1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-tryptophan (0.5-1.0 g t.i.d.)
Study: 707970
Drug: Doxepin (25-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxepin (25-50 mg t.i.d.)
Study: 707970
Drug: Chlorimipramine (25-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorimipramine (25-50 mg t.i.d.)
Study: 707970
Drug: Pre-drug scores
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-drug scores (29 patients)
Study: 29997904
Drug: Non-directive supportive
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-directive supportive therapy (NDST)
Study: 29238824
Drug: Gabapentin (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (1200 mg preoperatively and 600 mg 3 times a day postoperatively)
Study: 29238824
Drug: Active placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active placebo (lorazepam, 0.5 mg preoperatively followed by inactive placebo postoperatively)
Study: 23043386
Drug: PEG‐IFN/ribavirin (P/R)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐IFN/ribavirin (P/R) for a total of 72 weeks with 24 weeks follow‐up off‐therapy
Study: 16784879
Drug: valdecoxib 10
Normalized name: valdecoxib 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: valdecoxib 10 mg qd
Study: 19411388
Drug: rofecoxib 25
Normalized name: rofecoxib 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rofecoxib 25 mg qd
Study: 10512278
Drug: Morphine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine plus lysine acetyl salicylate (LAS)
Study: 2030245
Drug: Parent-training treatment
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent-training treatment (average of 44.8 hours of professional contact, including 23.3 hours of phone contacts)
Study: 2030245
Drug: Service traditionally
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Service traditionally provided by the juvenile court and community (estimated more than 50 hours of treatment)
Study: 2030245
Drug: Parent-training treatment
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent-training treatment
Study: 21368587
Drug: Pregabalin 600
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin 600 mg
Study: 28835404
Drug: Erenumab 70
Normalized name: Erenumab 70 mg/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erenumab 70 mg every 4 weeks for up to 5 years
Study: 25815710
Drug: Daily walking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily walking (30-60 minutes to achieve 10,000 steps/day for 4 weeks)
Study: 19122539
Drug: Maintenance treatment
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance treatment with antidepressants
Study: 19122539
Drug: Long-term pharmacological
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term pharmacological treatment
Study: 17910229
Drug: Group 3:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 3: resin composite restoration with two horizontal self‐threading pins in the buccal cusp but without flowable composite
Study: 17910229
Drug: Group 4:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 4: resin composite restoration with two horizontal self‐threading pins in the buccal cusp and flowable composite with a thickness of 2 mm
Study: 15472792
Drug: Probiotic Lactobacillus
Normalized name: Probiotic Lactobacillus Acidophilus Caplets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic Lactobacillus rhamnosus GG (LGG) preparation (1-5 x 10^10 cfu/dose)
Study: 15472792
Drug: Probiotic Lactobacillus
Normalized name: Probiotic Lactobacillus Acidophilus Caplets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic Lactobacillus rhamnosus GG (LGG) preparation
Study: 2666475
Drug: Stimulant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulant therapy
Study: 8686677
Drug: Fränkel function
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fränkel function regulator or Harvold activator (treatment)
Study: 6862292
Drug: State of
Normalized name: Active state of complement enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: State of tumor capsules in Stage I
Study: 31916717
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (routine feeding protocol without any administration)
Study: 15846460
Drug: Montelukast 3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 3.5 mg intravenous dose in children
Study: 15846460
Drug: Montelukast 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 7 mg intravenous dose in adults
Study: 15846460
Drug: Montelukast 5.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 5.25 mg intravenous dose in children (suggested from trial simulations)
Study: 11916954
Drug: Acute Insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acute Insulin Response (AIR)
Study: 10328634
Drug: Low-dose vitamin-mineral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose vitamin-mineral tablets
Study: 9517520
Drug: Cisapride (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (10 mg three times daily for 3 days)
Study: 1761452
Drug: Ceftibuten 400
Normalized name: ceftibuten 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftibuten 400 mg once a day
Study: 1761452
Drug: Cefaclor 250
Normalized name: cefaclor 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor 250 mg every 8 h
Study: 6360773
Drug: Cicloxilic acid
Normalized name: cicloxilic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cicloxilic acid (240 mg/day for 1 month)
Study: 18715524
Drug: Rivaroxaban 40
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban 40 mg
Study: 27692128
Drug: BFC group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: BFC group (BUD/FM 160/4.5 μg twice daily)
Study: 27692128
Drug: ICS group
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICS group (budesonide 400 μg twice daily or equivalent dose of ICS)
Study: 22974412
Drug: Metformin glycinate
Normalized name: Glycine
DrugBank: Glycine (DB00145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metformin glycinate (1,050.6 mg once daily for the first month, then force-titrated to twice daily for the second month)
Study: 20349666
Drug: Propofol (50‐200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (50‐200 mg/kg/min)
Study: 15589485
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of simvastatin
Study: 15589485
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of simvastatin
Study: 10698809
Drug: Nortriptyline (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nortriptyline (25 mg/day to 100 mg/day)
Study: 10698809
Drug: Fluoxetine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (10 mg/day to 40 mg/day)
Study: 9083608
Drug: Fenfluramine (1.0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenfluramine (1.0, 1.5, or 2.0 mg/kg/day)
Study: 1938800
Drug: Methylphenidate (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (0.4 mg/kg/day)
Study: 19088952
Drug: Topical metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical metronidazole gel
Study: 26711545
Drug: Hypnosis combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypnosis combined with topical oropharyngeal anaesthesia (HYP group)
Study: 26711545
Drug: Topical oropharyngeal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical oropharyngeal anaesthesia only (CTRL group)
Study: 25218906
Drug: Olaparib monotherapy
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib monotherapy (400 mg twice daily)
Study: 25218906
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cediranib (30 mg daily) and olaparib (200 mg twice daily)
Study: 25218906
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (cediranib plus olaparib)
Study: 21175312
Drug: Apixaban 2.5
Normalized name: apixaban 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban 2.5 mg orally twice daily
Study: 21175312
Drug: Enoxaparin 40
Normalized name: ENOXAPARIN 40MG/0.4ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 40 mg subcutaneously every 24 hours
Study: 17427536
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg pioglitazone tablet (Glista)
Study: 17427536
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg pioglitazone tablet (Actos)
Study: 15580607
Drug: Pergolide 25
Normalized name: pergolide 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pergolide 25 mug twice daily
Study: 12530048
Drug: Gemcitabine 1000
Normalized name: gemcitabine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1000 mg/mq weekly on days 1 and 8, followed by a 2-week rest; Cisplatin 80 mg/mq on day 2 of each 28-day cycle.
Study: 9464215
Drug: Fluoxetine 10
Normalized name: fluoxetine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 10 mg/day for 1 week
Study: 9464215
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg/day for 5 weeks
Study: 7710018
Drug: Propofol 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2.0 mg.kg‐1
Study: 7710018
Drug: Thiopentone 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopentone 5.0 mg.kg‐1.min‐1
Study: 795696
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of 250 mg of lidocaine
Study: 31915807
Drug: Presatovir 200
Normalized name: Presatovir
DrugBank: Presatovir (DB12165)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presatovir 200 mg every 4 days for 5 doses
Study: 24686255
Drug: Fasinumab 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasinumab 0.1 mg/kg
Study: 24686255
Drug: Fasinumab 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasinumab 0.3 mg/kg
Study: 22362063
Drug: Very-low-protein diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very-low-protein diet (0.3 g/kg body weight per day) supplemented with ketoanalogues
Study: 22362063
Drug: Low-protein diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-protein diet (0.6 g/kg body weight per day)
Study: 20622031
Drug: Salmeterol/Fluticasone propionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol/Fluticasone propionate (SFP), 50/100 μg twice a day
Study: 20622031
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP), 200 μg twice a day
Study: 12932605
Drug: Potassium-sparing diuretics
Normalized name: Potassium
DrugBank: Potassium (DB14500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium-sparing diuretics (PSDs)
Study: 12932605
Drug: Non-potassium-sparing diuretics
Normalized name: Potassium
DrugBank: Potassium (DB14500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-potassium-sparing diuretics (non-PSDs)
Study: 12932605
Drug: Potassium-sparing diuretics
Normalized name: Potassium
DrugBank: Potassium (DB14500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium-sparing diuretics (PSDs) with or without non-potassium-sparing diuretics (non-PSDs)
Study: 7036278
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (vincristine, cyclophosphamide, and 5‐fluorouracil once a month for 12 months)
Study: 7036278
Drug: BCG immunotherapy
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG immunotherapy (150 mg BCG once a week for 1 year)
Study: 7036278
Drug: No complementary
Approvals — FDA: no, EMA: no, PMDA: no
Description: No complementary treatment (control group)
Study: 31020541
Drug: Oral Bifidobacterium
Normalized name: BIFIDOBACTERIUM
DrugBank: Bifidobacterium spp. (DB18530)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Bifidobacterium tetravaccine tablets (Live) for 2 months
Study: 22058190
Drug: Weekly counseling
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly counseling
Study: 20625319
Drug: More intense
Normalized name: polyurethane-35 (not more than MPA.S at 40 %)
Approvals — FDA: no, EMA: no, PMDA: no
Description: More intense antihypertensive treatment
Study: 20625319
Drug: Less intense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less intense antihypertensive treatment
Study: 16807281
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment for 6 months)
Study: 10599982
Drug: Gemfibrozil 600
Normalized name: gemfibrozil 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil 600 mg twice daily
Study: 10374554
Drug: Preoperative selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative selective vascular chemotherapy with routine quantity of FAM
Study: 8195821
Drug: Selegiline 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline 10 mg/day orally for 6 months
Study: 3035879
Drug: 1,25-dihydroxycholecalciferol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,25-dihydroxycholecalciferol (0.5 microgram daily)
Study: 3035879
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (400 IU daily)
Study: 28186943
Drug: Picture booklet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Picture booklet intervention used with a trained researcher and a carer present, used at least twice over 20 weeks.
Study: 28186943
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (control group) with a booklet provided at the end of the study.
Study: 25115507
Drug: Caffeine (split
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (split dose 2 × 3 mg kg(‐1))
Study: 21626050
Drug: Antipyrine clearance
Normalized name: Antipyrine
DrugBank: Antipyrine (DB01435)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipyrine clearance test (ACL) with oral antipyrine 10 mg/kg
Study: 21626050
Drug: Docetaxel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (75 mg/m(2)/3‐weekly or 35 mg/m(2)/weekly)
Study: 21626050
Drug: Docetaxel weekly
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel weekly patients
Study: 31308037
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (anti-infection treatment)
Study: 25475768
Drug: 0.2% Chlorohexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% Chlorohexidine gel (Group 2)